Cargando…
Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus
Immunosuppressed individuals can shed influenza virus for prolonged periods of time, leading to the frequent emergence of antiviral resistance. We evaluated the benefits of oseltamivir and favipiravir combination therapy compared to single antiviral agents and monitored the emergence of drug-resista...
Autores principales: | Baz, Mariana, Carbonneau, Julie, Rhéaume, Chantal, Cavanagh, Marie-Hélène, Boivin, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266789/ https://www.ncbi.nlm.nih.gov/pubmed/30400276 http://dx.doi.org/10.3390/v10110610 |
Ejemplares similares
-
The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution
por: Ormond, Louise, et al.
Publicado: (2017) -
Interferon Lambda Delays the Emergence of Influenza Virus Resistance to Oseltamivir
por: Medaglia, Chiara, et al.
Publicado: (2021) -
A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir
por: Abed, Yacine, et al.
Publicado: (2017) -
Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice
por: Park, Sehee, et al.
Publicado: (2014) -
Oseltamivir in human avian influenza infection
por: Smith, James R.
Publicado: (2010)